KR970704440A - 당뇨병 타입 ⅱ의 치료용 약물에의 케토코나졸 및 관련 물질의 용도(use of ketoconazole and related substances in medicaments for treatment of type ⅱ diabetes) - Google Patents

당뇨병 타입 ⅱ의 치료용 약물에의 케토코나졸 및 관련 물질의 용도(use of ketoconazole and related substances in medicaments for treatment of type ⅱ diabetes) Download PDF

Info

Publication number
KR970704440A
KR970704440A KR1019970700852A KR19970700852A KR970704440A KR 970704440 A KR970704440 A KR 970704440A KR 1019970700852 A KR1019970700852 A KR 1019970700852A KR 19970700852 A KR19970700852 A KR 19970700852A KR 970704440 A KR970704440 A KR 970704440A
Authority
KR
South Korea
Prior art keywords
ketoconazole
treatment
diabetes
type
related substances
Prior art date
Application number
KR1019970700852A
Other languages
English (en)
Other versions
KR100422162B1 (ko
Inventor
모린 페르
Original Assignee
얀 킨덤
메타볼릭 신드롬 아이 지비지 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀 킨덤, 메타볼릭 신드롬 아이 지비지 에이비 filed Critical 얀 킨덤
Publication of KR970704440A publication Critical patent/KR970704440A/ko
Application granted granted Critical
Publication of KR100422162B1 publication Critical patent/KR100422162B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

당뇨병 타입 Ⅱ의 치료용 약물 및 메타볼릭 신드롬(치명적인 쿼텟 또는 신드롬 X 또는 인슐린 저항 신드롬으로 또한 알려진)의 부분인 다른 위험 인자에 반작용하는 약물을 제조하기 위한, 케토코나줄과 유사하지만 사이드 체인을 가지며, 케토코나졸과 비교하여 생물학적 활성도에 영향을 미치지 않는, 변화된 분자 또는 케토코나졸의 용도.

Description

당뇨병 타입 Ⅱ의 치료용 약물에의 케토코나졸 및 관련 물질의 용도(USE OF KETOCONAZOLE AND RELATED SUBSTANCES IN MEDICAMENTS FOR TREATMENT OF TYPE Ⅱ DIABETES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 당뇨병 타입 Ⅱ의 치료 및 메타볼릭 신드롬(치명적인 쿼텟 또는 신드롬 X 또는 인슐린 저항 신드롬으로 또한 알려진)의 일부인 다른 위험 인자에 반작용하는 약물을 제조하기 위한, 케토코나졸과 유사하지만 사이드 체인을 가지며, 케토코나졸과 비교하여 생물학적 활성에 영향을 미치지 않는,변화된 분자 또는 케토코나졸의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700852A 1994-08-09 1994-08-09 케토코나졸을포함하는당뇨병타입ii의치료용약제 KR100422162B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020027008471A Division KR20030097598A (ko) 2002-06-28 1994-08-09 코르티솔 길항제를 포함하는 당뇨병 타입 ⅱ의 치료용약제

Publications (2)

Publication Number Publication Date
KR970704440A true KR970704440A (ko) 1997-09-06
KR100422162B1 KR100422162B1 (ko) 2004-07-07

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700852A KR100422162B1 (ko) 1994-08-09 1994-08-09 케토코나졸을포함하는당뇨병타입ii의치료용약제

Country Status (14)

Country Link
US (2) US5849740A (ko)
EP (2) EP0779810B8 (ko)
JP (1) JP3825469B2 (ko)
KR (1) KR100422162B1 (ko)
AT (1) ATE244009T1 (ko)
CA (1) CA2196174C (ko)
CZ (1) CZ285290B6 (ko)
DE (1) DE69432905T2 (ko)
DK (1) DK0779810T3 (ko)
ES (1) ES2202326T3 (ko)
NO (1) NO314616B1 (ko)
PT (1) PT779810E (ko)
SI (1) SI0779810T1 (ko)
WO (1) WO1996004912A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004912A1 (en) * 1994-08-09 1996-02-22 Metabolic Syndrome I Gbg Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
AU2002365122A1 (en) * 2001-08-23 2003-07-15 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
US7094792B2 (en) 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2053409A1 (en) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
MX2007008331A (es) * 2005-01-10 2008-01-14 Cortendo Invest Ab Publ Metodos y composiciones para el tratamiento de diabetes, sindrome metabolico y otras condiciones.
EP1976526A2 (en) * 2006-01-10 2008-10-08 Diobex, Inc. Methods and compositions for treating prostate cancer
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
BRPI0719835A2 (pt) * 2006-10-02 2014-05-06 Cortendo Invest Ab Enantiômero de cetoconazol em humanos
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
WO1996004912A1 (en) * 1994-08-09 1996-02-22 Metabolic Syndrome I Gbg Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
ES2202326T3 (es) 2004-04-01
DE69432905T2 (de) 2004-05-27
NO970567L (no) 1997-02-07
US6166017A (en) 2000-12-26
EP0779810B8 (en) 2003-09-17
CZ285290B6 (cs) 1999-06-16
JPH10510241A (ja) 1998-10-06
SI0779810T1 (en) 2003-12-31
AU695011B2 (en) 1998-08-06
DK0779810T3 (da) 2003-10-20
WO1996004912A1 (en) 1996-02-22
KR100422162B1 (ko) 2004-07-07
CZ36097A3 (en) 1997-06-11
EP1360960A1 (en) 2003-11-12
US5849740A (en) 1998-12-15
ATE244009T1 (de) 2003-07-15
EP0779810B1 (en) 2003-07-02
JP3825469B2 (ja) 2006-09-27
DE69432905D1 (de) 2003-08-07
CA2196174A1 (en) 1996-02-22
AU7711894A (en) 1996-03-07
NO314616B1 (no) 2003-04-22
EP0779810A1 (en) 1997-06-25
PT779810E (pt) 2003-11-28
NO970567D0 (no) 1997-02-07
CA2196174C (en) 2005-03-01

Similar Documents

Publication Publication Date Title
KR970704440A (ko) 당뇨병 타입 ⅱ의 치료용 약물에의 케토코나졸 및 관련 물질의 용도(use of ketoconazole and related substances in medicaments for treatment of type ⅱ diabetes)
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
KR920000315A (ko) 모다피닐의 용도
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
NO902840D0 (no) Middel for transdermal applikasjon som inneholder gestoden
DE69420967T2 (de) Lösung zur verwendung gegen den pilzbefall von nägeln
BR0317038A (pt) Material elástico, laminado elástico e produto absorvente de uso pessoal
KR890011606A (ko) 항응고제
BR9809951A (pt) Método para tratamento da obesidade
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
BR9712306A (pt) Processo para preparação de um preparado de igm para aplicação endovenosa
KR970073602A (ko) 견피브로인을 함유하는 인슐린 비의존형 당뇨병 치료제
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
KR930702016A (ko) 골다공증 치료제
KR980000460A (ko) 외피용 약제 조성물
BR9708552A (pt) Fita avançada de redução de som.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR890012643A (ko) 루신(Leucine)에 의한 생체에너지원 대체 용도
MXPA05006326A (es) Derivados diversamente sustituidos de guanidina, y su uso como medicamentos con actividad anti-diabetes y/o anti-obesidad.
BR9611639A (pt) Processo para redução parcelas de produtos colaterais em carbendazima pelo acréscimo de agentes de diazotização

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
A107 Divisional application of patent
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080130

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee